Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Barcelona
Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 111 Madrid 100 Valencia 42 Santiago Compostela 30 Seville 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Merck Sharp & Dohme LLC113 Novartis Pharmaceuticals111 Janssen Research & Development, LLC96 Hoffmann-La Roche85 Clear sponsor filter
Site location
Barcelona111 Madrid100 Valencia42 Santiago Compostela30 Seville30
All 75 locations
Target enrolment
to

Trials with a site in Barcelona

111 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Barcelona
2026-08-06
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Barcelona
2026-07-10
Recruiting
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
NCT07683065Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
Novartis Pharmaceuticals
Observational
150
Badalona, Barcelona, Madrid, Málaga
2026-07-08
Recruiting
Novartis Pharmaceuticals
Phase 2
60
Barcelona, Madrid, Murcia
2026-06-26
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Pozuelo de Alarcón, Barcelona, Madrid
2026-06-12
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Pamplona, Barcelona, Madrid, Valencia
2026-06-08
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Pozuelo de Alarcón, Barcelona, Las Palmas GC, Madrid, Seville
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Barcelona, Las Palmas GC, Madrid
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Pozuelo de Alarcón, Barcelona, Madrid
2026-05-19
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Barcelona, Madrid
2026-04-28
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Barcelona, Alicante, Córdoba, Madrid, Valencia
2026-04-16
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Pamplona, Valencia, Barcelona, Seville
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Palma, Barcelona, Madrid, Seville
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Santiago de Compostela, Barcelona, Córdoba, Madrid, Pontevedra, Seville
2026-03-09
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Barcelona, Madrid
2025-12-29
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Granada, L'Hospitalet de Llobregat, Barcelona, Madrid
2025-12-05
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Albacete, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz, El Palmar
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Esplugues, A Coruña, Barcelona, Madrid
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Santander, Badajoz, Lugo, Barcelona, Córdoba
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Granada, El Palmar, Barcelona, Seville
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Barcelona, Madrid
2025-06-20
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Santiago Compostela, Barcelona
2025-06-12
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca
2025-05-30
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Barcelona, Pamplona, Alicante, Madrid
2025-05-22
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Barcelona
2025-05-19
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC
2025-04-30
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Barcelona
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Granada, Palma, Barcelona, Granollers, Las Palmas GC, Madrid, Pontevedra, Seville
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Barcelona, Córdoba, Madrid, Valencia
2025-02-24
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Barcelona, Lleida, Madrid, Málaga, Valencia
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Cadiz, Badalona, Sabadell, Barcelona, Manises, Valencia, Madrid
2025-01-31
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Barcelona, Madrid, Málaga
2024-12-12
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 1
106
Santiago Compostela, Majadahonda, Barcelona
2024-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Santiago Compostela, Marbella, Toledo, Barcelona, Las Palmas de Gran C, Seville
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia
2024-10-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Barcelona, Madrid
2024-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Málaga, Valencia, Barcelona, Madrid, Salamanca
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 1
54
Santiago Compostela, Barcelona, Madrid
2024-10-08
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
L'Hospitalet de Llobregat, Barcelona, Madrid
2024-08-14
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
49
L'Hospitalet de Llobregat, Barcelona, Madrid
2024-01-03
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Santiago, Granada, Barcelona, Alicante, Madrid, Valencia
2023-12-07
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Palma, Esplugues, L'Hospitalet de Llobregat, A Coruña, Barcelona, Madrid
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Granada, Barcelona, Córdoba, Las Palmas GC, Valencia
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 1
28
L'Hospitalet de Llobregat, Barcelona, Madrid
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Pamplona, Almería, Barcelona, Madrid, Salamanca
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Barakaldo, Barcelona, Burgos, Madrid
2023-08-25
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Barcelona
2023-08-16
Recruiting
Novartis Pharmaceuticals
Phase 4
700
L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia
2023-08-14
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Manises, Barcelona, Girona, Lleida, Lugo, Madrid, Seville
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Barcelona, Madrid, Valencia
2023-06-27
Recruiting
Novartis Pharmaceuticals
Phase 3
200
Esplugues, Sabadell, Barcelona, Córdoba, Madrid, Málaga
2023-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Badalona, Barcelona, Madrid
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 1
38
Valencia, Barcelona
2023-02-23
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Barcelona, Madrid, Murcia, Salamanca, Seville
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Barcelona, Murcia
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Barcelona
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Barcelona, Alicante, Las Palmas GC, Madrid, Valencia
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Barcelona, Madrid
2022-12-06
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Barcelona
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Barcelona, Madrid
2022-10-24
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Barcelona
2022-10-03
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Recruiting
Novartis Pharmaceuticals
Phase 2
42
Esplugues, Sabadell, Mérida, Barcelona
2022-08-29
Recruiting
Novartis Pharmaceuticals
Phase 2
240
Port de Sagunt, Barcelona, Ciudad Real, Madrid, Seville
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Barcelona, Madrid, Málaga
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
610
A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 1
63
Granada, Barcelona, Madrid
2022-05-10
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Badajoz, Pozuelo de Alarcón, Oviedo, A Coruña, Barcelona, Madrid, Málaga, Zaragoza
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Cadiz, Seville, Barcelona, Sant Joan Despí, Salt, Alcorcón, Getafe, Majadahonda
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Barcelona
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Granada, El Palmar, Pamplona, Barcelona, Madrid
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Pamplona, Barcelona, Salamanca
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Barcelona, Port de Sagunt, Madrid, Málaga, Seville
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Santiago Compostela, Donostia / San Sebastian, Barcelona
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga
2021-06-15
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Barcelona, Madrid
2021-06-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia
2021-06-09
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Oviedo, Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2021-04-09
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Port de Sagunt, Barcelona, Lugo, Madrid, Majadahonda
2021-03-15
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Barcelona, Madrid, Sagunto, Seville, Valencia
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Pamplona, Barcelona, Madrid, Seville
2019-10-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
254
Barcelona, Madrid
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Barcelona
2019-05-07
Active, closed
Novartis Pharmaceuticals
Phase 2
248
Granada, Sabadell, Manises, Barcelona, Las Palmas GC, Valencia
2019-02-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Cadiz, L'Hospitalet de Llobregat, Barcelona, Donostia / San Sebastian, Salt, Majadahonda, Pozuelo de Alarcón, El Palmar
2018-12-28
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Barcelona, Madrid, Valencia
2018-01-26
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2017-08-23
Active, closed
Novartis Pharmaceuticals
Phase 4
233
A Coruña, Barcelona, Madrid, Málaga
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Barcelona
2015-05-27
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Barcelona
2015-03-06
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Barcelona, Pamplona, Salamanca
2015-03-05
Rows per page Showing 1–111 of 111
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 111 of those studies with a site in Barcelona that also match the filters currently applied.

How many clinical trials are recruiting in Barcelona?

44 of the 111 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 67 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barcelona), 111 studies
PhaseStudiesRecruitingShare
Phase 3502045%
Phase 222919.8%
Phase 117415.3%
Phase 1/214512.6%
Phase 4645.4%
Observational110.9%
Phase 2/3110.9%

Most active sponsors

Lead sponsors with the most studies (Barcelona)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals11144
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.